Last update Sept. 4, 2022
Dolasetron is an antinauseant and antiemetic, 5-HT3 antagonist, used in chemotherapy and postoperatively. Oral or intravenous administration.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (moderately high molecular weight and wide volume of distribution) make it highly unlikely that significant quantities will pass into breast milk.
Although some author considers it probably compatible (Mahadevan 2006), until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable (Pistilli 2013), especially during the neonatal period and in the event of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM